Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03461328
Recruitment Status : Completed
First Posted : March 12, 2018
Last Update Posted : January 9, 2019
Information provided by (Responsible Party):
Abeer Ahmed, MD, Cairo University

Brief Summary:
Chronic Obstructive Pulmonary Disease [COPD] is a major cause of chronic morbidity and mortality worldwide. COPD is characterized by persistent progressive airflow limitation that adversely affects the ventilation/perfusion (V/Q) matching and mechanics of the respiratory muscles and leads to hypoventilation and reduced gas transfer. COPD was identified as a significant comorbidity associated with increased incidences of postoperative pulmonary complications and prolonged hospital stay. MgSO4 either intravenous or inhalational has been shown to promote bronchodilation and to improve lung function in asthmatic patients. MgSO4 either intravenous or inhalational has been shown to promote bronchodilation and to improve lung function in asthmatic patients. Administration of MgSO4 in patients with stable COPD was associated with reduced lung hyperinflation and improvement of respiratory muscle strength. This randomized control trial is designed to assess the effect of intravenous MgSO4 infusion on oxygenation and pulmonary mechanics and incidence of postoperative pulmonary complications and length of hospital stay in patients with COPD undergoing cancer larynx surgery.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Diseases Drug: Magnesium Sulphate Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Intra-operative intravenous infusion of magnesium sulphate in patients with chronic obstructive pulmonary diseases undergoing total laryngectomy and assess the influence on arterial oxygenation and pulmonary Mechanics in
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effect of Intravenous Infusion of Magnesium Sulphate on Arterial Oxygenation and Pulmonary Mechanics in Patients With Chronic Obstructive Pulmonary Diseases Undergoing Cancer Larynx Surgery. A Randomized Controlled Trial
Actual Study Start Date : April 20, 2018
Actual Primary Completion Date : October 20, 2018
Actual Study Completion Date : November 20, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: Mg-group
10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
Drug: Magnesium Sulphate
intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.

No Intervention: Control group
In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.

Primary Outcome Measures :
  1. lung oxygenation [ Time Frame: over a period of 6-8 hours, from the time of induction of general anesthesia until time of patients discharge from the PACU. ]
    PaO2/FiO2 immediately after arrival to the PACU

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing cancer larynx surgery (partial laryngectomy, total laryngectomy with or without neck dissection).
  • Age more than 40 years old
  • ASA physical status II and III.
  • Diagnosed as having COPD by preoperative spirometry. The classification is bases on the post-bronchodilators forced expiratory volume in the first second (FEV1). Mild COPD is diagnosed when FEV1 is > 80% of predicted while moderate COPD is diagnosed when FEV1 is < 80% and > 50% of predicted and sever COPD is diagnosed when FEV1 is < 50% and > 30% of predicted

Exclusion Criteria:

  • o Patients with heart failure.

    • History with arrhythmias or treatment with antiarrhythmic drugs.
    • Patient with heart block or on beta blockers or calcium channel blockers.
    • Patients with impaired renal function (creatinine > 2)
    • Patients with impaired liver function (ALT more than 2 folds).
    • Patient with combined restrictive and obstructive pulmonary disease.
    • Patients with preoperative tracheostomy.
    • Patients with huge mass obstructing > 50% of the view. (due to its influence on the spirometry measurements).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03461328

Anesthesia department - Faculty of medicine- Cairo University
Cairo, Egypt
Sponsors and Collaborators
Cairo University

Responsible Party: Abeer Ahmed, MD, Assistant Professor of Anesthesia and SICU - Faculty of Medicine - Cairo University, Cairo University Identifier: NCT03461328     History of Changes
Other Study ID Numbers: N-76-2017
First Posted: March 12, 2018    Key Record Dates
Last Update Posted: January 9, 2019
Last Verified: January 2019

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Abeer Ahmed, MD, Cairo University:
magnesium sulphate, chronic obstructive pulmonary diseases

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents